Market Research Report
Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022
|Published by||GlobalData||Product code||244298|
|Published||Content info||62 Pages
|Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022|
|Published: July 31, 2013||Content info: 62 Pages||
This publication has been discontinued on February 2, 2017.
GlobalData has released its new PharmaPoint Drug Evaluation report, "Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Namenda (memantine hydrochloride) is a first-in-class medication for AD with a unique MOA compared with the currently available drugs. It is an orally-active NMDA receptor antagonist and was the first, and at the time, the only, medication approved for the treatment of moderate to severe dementia of the Alzheimer's type.